PreDxion Bio
DefunctYC S17San Francisco, US · Founded 2017 · 6 employees · 1 known investors
PreDxion Bio develops rapid diagnostic tests using saliva samples and a scalable semiconductor-based platform, initially targeting SARS-CoV-2 detection for asymptomatic and presymptomatic individuals, with broader applications in monitoring immune response markers in critically ill patients and predicting complications from cell therapies.
HealthtechMedical DevicesMicrofluidicsNanosensorsCOVID-19United States of AmericaAmerica / CanadaPartly Remote
Founders & leadership· Y Combinator alumni (S17)
PreDxion Bio was founded in 2017 by Walker McHugh and Timothy Cornell.
WM
Walker McHughin𝕏FounderHe holds an undergraduate degree in immunology and a graduate degree from the Medical Product Development Program at the University of Michigan College of Engineering.
TC
Timothy CornellinFounder
Investors · 1
Frequently asked questions
- What does PreDxion Bio do?
- PreDxion Bio develops rapid diagnostic tests using saliva samples and a scalable semiconductor-based platform, initially targeting SARS-CoV-2 detection for asymptomatic and presymptomatic individuals, with broader applications in monitoring immune response markers in critically ill patients and predicting complications from cell therapies.
- Who founded PreDxion Bio?
- PreDxion Bio was founded by Walker McHugh, Timothy Cornell in 2017.
- Who are PreDxion Bio's investors?
- PreDxion Bio's investors include Y Combinator.
- Where is PreDxion Bio headquartered?
- PreDxion Bio is headquartered in San Francisco, US.